FDA says Mylan's EpiPen is in shortage in U.S.
(Reuters) - U.S. regulators said on Wednesday that Mylan NV's EpiPen products are in shortage due to manufacturing delays that are creating intermittent supply constraints of the emergency allergy treatment.
from Reuters: Health News https://reut.rs/2rvqaz7
http://bit.ly/2zwRqiM